▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Stocks & Bonds

[STOCK WATCH] NeoPharm rises 6.46%

  • PUBLISHED :February 14, 2017 - 14:51
  • UPDATED :February 14, 2017 - 18:20
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print
[THE INVESTOR] As of Feb. 14 02:25 P.M., NeoPharm increased 6.46%, compared with yesterday, to 25,550 won. It had increased 0.99% through the past month. Standard deviation, the variableness index, was 2.3% over the same period over one month.

Compared with its close competitors within the same industry, KOSDAQ, the monthly earnings rate of NeoPharm was considerably higher than that of its peer group's, while its volatility within 1 month was at a proper rate. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was 0.4. Though the volatility did not differ from the median, the high return lead the return-on-risk to a fair value. Moreover, compared with the KOSDAQ industry, the return-on-risk is much better than the industrial mean, -3.5, and thus the industrial comparison performance was positive.

Comparing industry to the market, the KOSDAQ industry including NeoPharm records lower volatility and earning rate than Chemicals. In other words, the industry was safer and the rate of decrease is smaller than that of the market. 

By HeRo (hero@heraldcorp.com)
This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.

EDITOR'S PICKS